DGAP-News : Newron und Zambon unterzeichnen -2-

und Brasilien. Das Unternehmen hat heute einen starken Fokus auf die Behandlung von seltenen Krankheiten sowie die 
Produktion von Spezialpharmazeutika, zusätzlich zu Atemwegserkrankungen, Schmerztherapie und Frauenheilkunde. Zambon 
wurde 1906 in Italien gegründet und zählt heute rund 2.500 Mitarbeiter in aller Welt. Für weitere Informationen 
besuchen Sie bitte www.zambon.com 
 
Bitte kontaktieren Sie für weitere Informationen: 
Newron: 
Stefan Weber - CEO 
[phone] - [e-mail] 
Großbritannien/Europa: 
Simon Conway / Natalie Garland-Collins 
FTI Consulting 
[phone] [e-mail] 
Schweiz: 
Valentin Handschin, IRF Reputation 
[phone] - [e-mail] 
Deutschland/Europa: 
Anne Hennecke, MC Services 
[phone] - [e-mail] 
USA: 
Paul Sagan, LaVoieHealthScience 
[phone], Ext. 112 - [e-mail] 
Zambon: 
Valentina Saffioti - Global Pharma Communication 
[phone] - [e-mail] 
Wichtige Hinweise: 
This document contains forward-looking statements, including (without limitation) about (1) Newron's ability to develop 
and expand its business, successfully complete development of its current product candidates and current and future 
collaborations for the development and commercialisation of its product candidates and reduce costs (including staff 
costs), (2) the market for drugs to treat CNS diseases and pain conditions, (3) Newron's anticipated future revenues, 
capital expenditures and financial resources, and (4) assumptions underlying any such statements. In some cases, these 
statements and assumptions can be identified by the fact that they use words such as "will," "anticipate," "estimate," 
"expect," "project," "intend," "plan," "believe," "target," and other words and terms of similar meaning. All 
statements, other than historical facts, contained herein regarding Newron's strategy, goals, plans, future financial 
position, projected revenues and costs and prospects are forward-looking statements. By their very nature, such 
statements and assumptions involve inherent risks and uncertainties, both general and specific, and risks exist that 
predictions, forecasts, projections and other outcomes described, assumed or implied therein will not be achieved. 
Future events and actual results could differ materially from those set out in, contemplated by or underlying the 
forward-looking statements due to a number of important factors. These factors include (without limitation) (1) 
uncertainties in the discovery, development or marketing of products, including without limitation negative results of 
clinical trials or research projects or unexpected side effects, (2) delay or inability in obtaining regulatory 
approvals or bringing products to market, (3) future market acceptance of products, (4) loss of or inability to obtain 
adequate protection for intellectual property rights, (5) inability to raise additional funds, (6) success of existing 
and entry into future collaborations and licensing agreements, (7) litigation, (8) loss of key executive or other 
employees, (9) adverse publicity and news coverage, and (10) competition, regulatory, legislative and judicial 
developments or changes in market and/or overall economic conditions. Newron may not actually achieve the plans, 
intentions or expectations disclosed in forward-looking statements, and assumptions underlying any such statements may 
prove wrong. Investors should therefore not place undue reliance on them. There can be no assurance that actual results 
of Newron's research programmes, development activities, commercialisation plans, collaborations and operations will 
not differ materially from the expectations set out in such forward-looking statements or underlying assumptions. 
Newron does not undertake any obligation to publicly update or revise forward-looking statements except as may be 
required by applicable regulations of the SIX Swiss Exchange, where the shares of Newron are listed. This announcement 
is not an offer for sale of securities in the United States, Canada, Australia or Japan or any other jurisdiction where 
such an offer or solicitation would otherwise be unlawful. The securities referred to herein may not be sold in the 
United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. 
Newron does not intend to register any of its securities in the United States or to conduct a public offering of its 
securities in the United States. This document does not contain or constitute an offer or invitation to purchase or 
subscribe for any securities of Newron and no part of this document shall form the basis of or be relied upon in 
connection with any contract or commitment whatsoever. 
=---------------------------------------------------------------------------------------------------------------------- 
2021-03-15 Veröffentlichung einer Corporate News/Finanznachricht, übermittelt durch DGAP - ein Service der EQS Group 
AG. 
Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. 
Die DGAP Distributionsservices umfassen gesetzliche Meldepflichten, Corporate News/Finanznachrichten und 
Pressemitteilungen. 
Medienarchiv unter http://www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 

1175412 2021-03-15

(END) Dow Jones Newswires

March 15, 2021 02:01 ET (06:01 GMT)